Industry update
Shanghai Junshi Biosciences Co.Ltd(688180) covid-19 oral drug is about to carry out international multicenter phase II / III clinical trial. On January 26, 2022, the research alliance of national infectious disease medical centers was established. Its No. 001 study is the international multicenter phase II / III clinical study of covid-19 drug vv116 of Shanghai Junshi Biosciences Co.Ltd(688180) . It is expected that the drug is expected to rapidly promote clinical trials and complete the registration application outside China.
Yanyeyi released 3CL oral drug data. On January 31, 2022, yanyeyi announced the preclinical and clinical research data of covid-19 oral drug and 3CL protease inhibitor s-217622. In vitro data showed that s-217622 was generally effective against mutant strains. Clinical data showed that s-217622 rapidly reduced virus titer and viral RNA copy number. At present, yanyeyi is continuing the phase IIb / III study and communicating with FDA and EMA about the global phase III clinical trial.
EBO / Watson mRNA vaccine phase I data published. On January 24, 2022, the phase I clinical data of Arbo / Watson’s covid-19 mRNA vaccine arcov were published in the lancet microorganism. Arcov was safe, well tolerated and strongly induced immune response at all five doses. In November 2021, Watson has registered the phase IIIB clinical trial of arcov. On January 28, 2022, Watson announced to cooperate with Shanghai Blue Magpie biology to develop covid-19 virus variant mRNA vaccine.
Covid-19 epidemic continued to recur worldwide. The global new cases began to callback at the end of January. The increase in the number of covid-19 inpatients was less than that of new cases, and the mortality of covid-19 patients remained within 1%. The global vaccination rate rose to 61%, and the average vaccination rate of booster injection exceeded 10%.
The proportion of Omicron continues to rise, and the new subspecies ba 2. It is more transmissible. The proportion of Omicron in the world has risen to 71%, and accounts for more than 90% in many countries. It is the mainstream strain at present. A new subspecies of Omicron, BA The transmissibility of 2 is 33% higher than that of the original variant of Omicron. At present, 35000 infected patients have been found in 57 countries.
Brief comment
The normalization of the epidemic situation and the expectation of influenza are optimistic about the volume of oral covid-19 drugs. Vaccine, neutralizing antibody and oral covid-19 drugs work together to normalize the epidemic and influenza. Based on the therapeutic mechanism, accessibility and economy of oral drugs, we continue to be optimistic about the application prospect of oral small molecule covid-19 drugs.
A number of domestic and foreign oral covid-19 drugs are about to enter the mass production stage: ① the original research supply chain continues to increase the supply chain; ② Through the equity grant of MPP platform, generic pharmaceutical enterprises and supply chain enterprises obtain the rights and interests of generic pharmaceutical production and sales; ③ The layout of covid-19 oral drugs in China is rich, and the research and development is gradually promoted.
The MPP platform began to review and grant the rights and interests of oral covid-19 generic drugs one after another, and paid attention to the expectation of large-scale generic drugs: the MPP platform granted 27 Chinese and foreign enterprises to produce molnupiravir, an oral covid-19 drug, and Pfizer’s generic drug application for paxlovid, an oral covid-19 drug, is also under review.
With oral covid-19 drugs (original research + imitation), we are optimistic about the large-scale expectation of cdmo in the upstream of the pharmaceutical industry and related products in the upstream fine chemical supply chain. Investment advice
It is suggested to pay attention to: Wuxi Apptec Co.Ltd(603259) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Zhejiang Ausun Pharmaceutical Co.Ltd(603229) , Porton Pharma Solutions Ltd(300363) , Brightgene Bio-Medical Technology Co.Ltd(688166) .
Risk tips
Covid-19 epidemic development and change risk, product R & D data and progress are less than expected risk, product capacity and sales are less than expected risk, government orders are less than expected risk, policy risk, etc.
